title: [Advanced hepatocellular carcinoma: importance of clinical trials].
abstract: In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date. Sorafenib is a targeted therapy mainly blocking tumor vascularisation. Sorafenib is currently used for inoperable or advanced stages of hepatocellular carcinoma, as well for hepatocellular carcinoma recurrence when the disease is diffuse or multifocal. Current clinical trials are designed to identify new antitumor molecules active in hepatocellular carcinoma that could enrich the therapeutic armamentarium in addition to sorafenib.
authors.forename: V
authors.initials: V
authors.lastname: Aedo
authors.forename: V
authors.initials: V
authors.lastname: Cristina
authors.forename: E
authors.initials: E
authors.lastname: Raymond
authors.forename: S
authors.initials: S
authors.lastname: Faivre
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018450:Disease Progression; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D018579:Patient Selection; D010671:Phenylurea Compounds; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib